• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

作为 2016 年 SENTRY 抗菌药物监测计划的一部分，对来自美国和欧洲的临床分离株进行了奥马环素活性测试的监测。

Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe as Part of the 2016 SENTRY Antimicrobial Surveillance Program.

机构信息

JMI Laboratories, North Liberty, Iowa, USA.

University of Iowa, Iowa City, Iowa, USA.

出版信息

Antimicrob Agents Chemother. 2018 Mar 27;62(4). doi: 10.1128/AAC.02327-17. Print 2018 Apr.

DOI:10.1128/AAC.02327-17
PMID:29378719
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5913935/
Abstract

Omadacycline was tested against 21,000 bacterial isolates collected prospectively from medical centers in Europe and the United States during 2016. Omadacycline was active against (MIC/MIC, 0.12/0.25 mg/liter), including methicillin-resistant (MRSA); streptococci (MIC/MIC, 0.06/0.12 mg/liter), including , viridans group streptococci, and beta-hemolytic streptococci; , including (MIC/MIC, 0.5/2 mg/liter); (MIC/MIC, 1/1 mg/liter); and (MIC/MIC, 0.25/0.25 mg/liter). Omadacycline merits further study in serious infections where resistant pathogens may be encountered.

摘要

奥马环素针对 2016 年期间从欧洲和美国医疗中心前瞻性收集的 21000 株细菌分离株进行了测试。奥马环素对（MIC/MIC，0.12/0.25 毫克/升）具有活性，包括耐甲氧西林金黄色葡萄球菌（MRSA）；链球菌（MIC/MIC，0.06/0.12 毫克/升），包括肺炎链球菌、草绿色链球菌和β溶血性链球菌；肠球菌（MIC/MIC，0.5/2 毫克/升）；流感嗜血杆菌（MIC/MIC，1/1 毫克/升）；和淋病奈瑟菌（MIC/MIC，0.25/0.25 毫克/升）。奥马环素在可能遇到耐药病原体的严重感染中值得进一步研究。

相似文献

1
Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe as Part of the 2016 SENTRY Antimicrobial Surveillance Program.作为 2016 年 SENTRY 抗菌药物监测计划的一部分，对来自美国和欧洲的临床分离株进行了奥马环素活性测试的监测。
Antimicrob Agents Chemother. 2018 Mar 27;62(4). doi: 10.1128/AAC.02327-17. Print 2018 Apr.
2
Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016 to 2018.对来自美国和欧洲的临床分离株进行奥马环素活性测试的监测：来自 SENTRY 抗菌监测计划的报告，2016 年至 2018 年。
Antimicrob Agents Chemother. 2020 Apr 21;64(5). doi: 10.1128/AAC.02488-19.
3
Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017.对来自美国和欧洲的临床分离株进行奥马环素活性检测的监测：来自 SENTRY 抗菌监测计划的 2017 年结果。
J Glob Antimicrob Resist. 2019 Dec;19:56-63. doi: 10.1016/j.jgar.2019.02.017. Epub 2019 Feb 27.
4
Antimicrobial Activity of Omadacycline Tested against Clinical Bacterial Isolates from Hospitals in Mainland China, Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013 to 2016).奥马环素对中国大陆、香港和台湾地区医院临床分离细菌的抗菌活性研究：SENTRY 抗菌监测计划（2013 年至 2016 年）的结果。
Antimicrob Agents Chemother. 2019 Feb 26;63(3). doi: 10.1128/AAC.02262-18. Print 2019 Mar.
5
Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010).检测亚太地区和南非分离的致皮肤软组织感染和社区获得性呼吸道感染的细菌分离株的抗菌活性：头孢洛林和比较剂（2010 年）。
Diagn Microbiol Infect Dis. 2013 May;76(1):61-8. doi: 10.1016/j.diagmicrobio.2013.01.005. Epub 2013 Mar 25.
6
Surveillance of Omadacycline Activity against Clinical Isolates from a Global Collection (North America, Europe, Latin America, Asia-Western Pacific), 2010-2011.2010 - 2011年对来自全球范围（北美、欧洲、拉丁美洲、亚洲 - 西太平洋）的临床分离株进行的奥玛环素活性监测。
Antimicrob Agents Chemother. 2017 Apr 24;61(5). doi: 10.1128/AAC.00018-17. Print 2017 May.
7
Surveillance of omadacycline activity tested against clinical isolates from the USA: report from the SENTRY Antimicrobial Surveillance Program, 2019.对美国临床分离株进行奥马环素活性检测的监测：来自 SENTRY 抗菌监测计划的报告，2019 年。
J Glob Antimicrob Resist. 2021 Dec;27:337-351. doi: 10.1016/j.jgar.2021.09.011. Epub 2021 Nov 12.
8
Activities of Omadacycline and Comparator Agents against Staphylococcus aureus Isolates from a Surveillance Program Conducted in North America and Europe.奥玛环素及对照药物对从北美和欧洲开展的一项监测项目中分离出的金黄色葡萄球菌的活性。
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02411-16. Print 2017 Mar.
9
Results from the Solithromycin International Surveillance Program (2014).索利霉素国际监测项目（2014年）的结果。
Antimicrob Agents Chemother. 2016 May 23;60(6):3662-8. doi: 10.1128/AAC.00185-16. Print 2016 Jun.
10
Activity of the Novel Aminomethylcycline KBP-7072 and Comparators against 1,057 Geographically Diverse Recent Clinical Isolates from the SENTRY Surveillance Program, 2019.新型氨甲基环素KBP-7072及对照物对2019年哨兵监测计划中1057株来自不同地理位置的近期临床分离株的活性
Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0139721. doi: 10.1128/AAC.01397-21. Epub 2021 Oct 11.

引用本文的文献

1
A matched pilot cohort study of intravenous omadacycline in the treatment of severe pneumonia associated with carbapenem-resistant .一项关于静脉注射奥马环素治疗耐碳青霉烯类严重肺炎的配对前瞻性队列研究。
Front Microbiol. 2025 Jul 23;16:1597860. doi: 10.3389/fmicb.2025.1597860. eCollection 2025.
2
Omadacycline exhibits anti-inflammatory properties and improves survival in a murine model of post-influenza MRSA pneumonia.奥马环素具有抗炎特性，并能提高流感后耐甲氧西林金黄色葡萄球菌肺炎小鼠模型的存活率。
Antimicrob Agents Chemother. 2025 Sep 3;69(9):e0046925. doi: 10.1128/aac.00469-25. Epub 2025 Aug 4.
3
Assessment of pharmacokinetics-pharmacodynamics to support omadacycline dosing regimens for the treatment of patients with acute bacterial skin and skin structure infections.评估药代动力学-药效学，以支持奥马环素治疗治疗急性细菌性皮肤和皮肤结构感染患者的给药方案。
Antimicrob Agents Chemother. 2024 Sep 4;68(9):e0128123. doi: 10.1128/aac.01281-23. Epub 2024 Jul 31.
4
Bedaquiline for treatment of non-tuberculous mycobacteria (NTM): a systematic review and meta-analysis.贝达喹啉治疗非结核分枝杆菌（NTM）：系统评价和荟萃分析。
J Antimicrob Chemother. 2024 Feb 1;79(2):211-240. doi: 10.1093/jac/dkad372.
5
New Antimicrobials for Gram-Positive Sustained Infections: A Comprehensive Guide for Clinicians.用于革兰氏阳性持续性感染的新型抗菌药物：临床医生综合指南
Pharmaceuticals (Basel). 2023 Sep 15;16(9):1304. doi: 10.3390/ph16091304.
6
Omadacycline for treatment of acute bacterial infections: a meta-analysis of phase II/III trials.奥马环素治疗急性细菌性感染的疗效：II/III 期临床试验的荟萃分析。
BMC Infect Dis. 2023 Apr 14;23(1):232. doi: 10.1186/s12879-023-08212-0.
7
Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae.评估奥马环素治疗方案用于治疗由肺炎链球菌和流感嗜血杆菌引起的社区获得性细菌性肺炎的药代动力学-药效学目标达成分析。
Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0221321. doi: 10.1128/aac.02213-21. Epub 2023 Mar 22.
8
A 68-Year-Old Man with Multiple Comorbidities Presents with a Weeping Wound of the Left Lower Extremity: A Case Report.一名患有多种合并症的68岁男性因左下肢渗液性伤口就诊：病例报告
J Community Hosp Intern Med Perspect. 2023 Jan 10;13(1):60-64. doi: 10.55729/2000-9666.1151. eCollection 2023.
9
Evaluating the Efficacy of Eravacycline and Omadacycline against Extensively Drug-Resistant Patient Isolates.评价依拉环素和奥马环素对广泛耐药患者分离株的疗效。
Antibiotics (Basel). 2022 Sep 23;11(10):1298. doi: 10.3390/antibiotics11101298.
10
Real-World, Multicenter Case Series of Patients Treated with Oral Omadacycline for Resistant Gram-Negative Pathogens.口服奥马环素治疗耐革兰氏阴性病原体患者的真实世界多中心病例系列
Infect Dis Ther. 2022 Aug;11(4):1715-1723. doi: 10.1007/s40121-022-00645-5. Epub 2022 May 14.

本文引用的文献

1
Surveillance of Omadacycline Activity against Clinical Isolates from a Global Collection (North America, Europe, Latin America, Asia-Western Pacific), 2010-2011.2010 - 2011年对来自全球范围（北美、欧洲、拉丁美洲、亚洲 - 西太平洋）的临床分离株进行的奥玛环素活性监测。
Antimicrob Agents Chemother. 2017 Apr 24;61(5). doi: 10.1128/AAC.00018-17. Print 2017 May.
2
Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections.奥马环素：一种用于治疗耐药细菌感染的新型氨基甲基环素类抗生素的研发
Future Microbiol. 2016 Oct;11:1421-1434. doi: 10.2217/fmb-2016-0100. Epub 2016 Aug 19.
3
Structure-activity relationship of the aminomethylcyclines and the discovery of omadacycline.氨甲基环素的构效关系及奥马环素的发现。
Antimicrob Agents Chemother. 2015 Nov;59(11):7044-53. doi: 10.1128/AAC.01536-15. Epub 2015 Sep 8.
4
In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline.奥马环素的体外和体内抗菌活性，一种新型的氨甲基环素。
Antimicrob Agents Chemother. 2014;58(2):1127-35. doi: 10.1128/AAC.01242-13. Epub 2013 Dec 2.
5
Mechanism of action of the novel aminomethylcycline antibiotic omadacycline.新型氨甲基环素抗生素奥马环素的作用机制
Antimicrob Agents Chemother. 2014;58(3):1279-83. doi: 10.1128/AAC.01066-13. Epub 2013 Sep 16.
6
Tetracycline therapy: update.四环素疗法：最新进展。
Clin Infect Dis. 2003 Feb 15;36(4):462-7. doi: 10.1086/367622. Epub 2003 Jan 28.